Tomorrow: The ASCO data that matter

Wednesday, June 3, 2026 | 11:00 AM - 1:00 PM ET

The most consequential data from ASCO are in, and we're on the ground breaking it down.

Revolution Medicines' pancreatic cancer data are as good as anticipated — bringing one oncologist to tears. China-based developer Akeso and its partner Summit Therapeutics posted a victory in lung cancer. And big oncology deals were inked before the conference even began, with Pfizer and BMS announcing deals for assets from Chinese companies.

Tomorrow, we'll sit down with experts behind the biggest oncology moves. Join us.

SPONSORED BY

Sponsorship opportunities are available.
Contact Meg at mestacio@endpointsnews.com to learn how you can support Endpoints at ASCO 2026.